Tenaya Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Tenaya Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($90.60M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($111.13M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($124.08M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($123.67M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($72.72M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($38.40M) | Mar 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($93.33M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($115.95M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($131.19M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($125.62M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($72.81M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($38.91M) | Mar 23, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.61M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $86.74M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $98.04M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $94.54M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $54.39M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $31.10M | Mar 23, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($68.26M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($90.50M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($102.07M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($104.42M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($60.81M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($35.45M) | Mar 23, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $618.0K | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.03M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $1.24M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $20.63M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $25.12M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $9.76M | Mar 23, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.92M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $119.94M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $170.52M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $278.95M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $314.19M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $148.16M | Mar 23, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.66M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $27.09M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $31.09M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $35.57M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $35.66M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $8.72M | Mar 23, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $123.27M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $92.85M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $139.42M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $243.38M | Mar 10, 2025 |
| FY2023 | Dec 31, 2021 | $278.53M | Mar 18, 2024 |
| FY2022 | Dec 31, 2020 | ($81.32M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | ($43.74M) | Mar 23, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($605.01M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($514.41M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($403.28M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($279.20M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($155.53M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($82.81M) | Mar 23, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.55M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $4.32M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $45.68M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $95.27M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $38.13M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $128.54M | Mar 23, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 8, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 8, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 216.76M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 86.54M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 68.33M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 66.86M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | 41.29M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 1.21M | Mar 23, 2022 |